拜瑪林製藥 BMRN 深 滬
等待開盤 07-18 09:30:00 美东时间
58.37
-0.020
-0.03%
華盛通- 最 高59.35
- 今 開58.48
- 成交量 132.48万股
- 最 低 58.22
- 昨 收 58.39
- 總市值 112.07亿
- 52周最高 94.85
- 市盈率 靜 26.44
- 換手率 0.69%
- 52周最低 52.93
- 委 比 -40.43%
- 總股本 1.92亿
- 歷史最高 151.75
- 量 比 0.81
- 振 幅 1.94%
- 歷史最低 23.735
- 每 手 1
- 風險率 9.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅94.06%！摩根大通上调BioMarin制药目标价至113美元，维持"超配"评级
今日重点评级关注：摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从108美元升至113美元；Oppenheimer：维持P10"跑赢大市"评级，目标价从20美元升至21美元
07-15 09:23
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $113
JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $108 to $113.
07-14 23:59
BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxisNo new safety signals observedSAN RAFAEL,
06-24 21:05
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion, Inc. has launched an underwritten public offering of its common stock and warrants. The offering includes the option for underwriters to purchase up to 15% more shares. The company plans to raise funds to support its diabetes and obesity treatments, icovamenib and BMF-650. The offering is expected to close on June 20, 2025, subject to market conditions. Jefferies is acting as sole book running manager.
06-17 20:33
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.
06-12 20:05
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Biomerica appoints Eric B. Chin to its Board of Directors, effective June 4, 2025. Mr. Chin, with over 20 years of financial experience in healthcare, will serve as Chair of the Audit Committee and member of other key committees. Currently Akido Labs' CFO, he helped raise $60 million in a recent financing. His加入加强了Biomerica的公司治理和财务监督，支持其商业化扩展。Biomerica is a global biomedical companydeveloping advanced diagnostic and therapeutic products,including...
06-06 13:30
BioMarin Agrees To Acquire Inozyme For $4.00/Shr In All-Cash Transaction For Total Consideration Of About $270M
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 DeficiencyFirst Pivotal Data Readout in Children Expected in Early 2026 with
05-16 19:33
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Childre...
05-16 19:30
Biomarin Pharma Announces New VOXZOGO Data Showing Tibial Bowing Improvement In Achondroplasia
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest
05-12 21:07
A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings
Looking into the current session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) sh...
05-03 04:00
